Anlage B: Personalhandbuch

Content

1. Lecturers from Pharmacy Department

Dr. Sebastian Braun	
Position	Lecturer (Hochdeputat)
Academic CV	Present position: Lecturer in the field of pharmaceutical development, manufacturing, quality management and project management, Heinrich-Heine University, Düsseldorf, since 2022 Promotion: Dr. rer. nat. Molecular Biology, Univerisity of Bielefeld, 2001-2006 Studies of Biology, Univerisity of Bielefeld, 1996-2001
Additional professions	Head of laboratory, project manager and head of manufacturing for clinical trial supplies for microneedle array patches, LTS Lohmann Therapie-Systeme AG, Andernach, 2020-2022 Subject Matter Expert and Technology Scout, tesa Labtec GmbH, Langenfeld, 2018-2020 Head of formulation and head of manufacturing for clinical trial supplies, tesa Labtec GmbH, Langenfeld, 2013-2018 Laboratory head and project manager, formulation development for dermal and transdermal patches, as well as orodisperisble and mucoadhesive buccal films, tesa Labtec GmbH, Langenfeld, 2009-2012 Laboratory head and project manager, formulation development and process development for dermal and transdermal patches, Acino AG, Miesbach, 2006-2009
Recent research topics	Microneedles Transdermal drug delivery Orodispersible films and mucoadhesive buccal films
Selected publications	-
Volunteer work in scientific organisations and academic self-government (past 5 years)	Subject Matter Expert for dermal and transdermal drug delivery system at the API Focus Group “Drug Delivery”, since 2019

Prof. Dr. Jörg Breitkreutz	
Position	University Professor (W2)
Academic CV	Present position (W2), University of Düsseldorf, since 2016 Declined professorship (W3), University of Kiel, 2016 Professorship (C3), Institute of Pharmaceutics and Biopharmaceutics, HHU Düsseldorf, 2004 Habilitation in Pharmaceutical Technology, University of Münster, 2004 Post-doc: University of Florida, Gainesville, USA, 1998 Promotion: Dr. rer.nat., Pharmaceutical Technology, University of Münster,1996 Diplompharmazeut, University of Greifswald,1992 Professional Pharmacy License, 1992 Studies of Pharmacy, University of Münster, 1987-1991 Studies of Informatics, University of Hagen, 1985-1986
Additional professions	Founder and shareholder of Ethicare GmbH, Haltern am See, Germany, since 2002 Founder and shareholder of Sepaserve GmbH, Münster, Germany, 2002-2006 (today: Phenomenex, USA) Head of Product Coordination (Deputy of Head of Production) at Thiemann Arzneimittel GmbH, Waltrop, Germany, 1996-1997
Recent research topics	3D printing of pharmaceuticals (Dr. Hans-Messer-Stiftung 2024-2025, BMBF ProMatLeben, 2018-2023) Orodispersible minitablets for paediatric use (EU FP7 RTN project LENA, 2013-2018; Aqumeldi®) Process analytical technologies in manufacturing of solids (DFG SPP2364 2022-2025, DBU 30816-31 and 31829-31, 2013-2018)
Selected publications	1. L.C. Lammerding, J. Breitkreutz (2023). Technical evaluation of precisely manufacturing customized microneedle array patches via inkjet drug printing, Int. J. Pharm. 642: 123173. 2. J. Niessen, A. López Mármol, R. Ismail, J.T. Schiele, K. Rau, A. Wahl, K. Sauer, O. Heinzerling, J. Breitkreutz, M. Koziolek (2023). Application of biorelevant in vitro assays for the assessment and optimization of ASD-based formulations for pediatric patients, Eur. J. Pharm. Biopharm. 185: 13-27.

	3. M. Fligge, I. Letofsky-Papst, M. Bäumers, A. Zimmer, J. Breitkreutz (2023). Personalized dermal patches – inkjet printing of nanosuspensions for individualized treatment of skin diseases. Int. J. Pharm. 630: 122382. 4. J. Kuck, J. Breitkreutz (2022). Impact of lubrication on key properties of orodispersible minitablets in comparison to conventionally sized tablets, Eur. J. Pharm. Biopharm. 180: 71-80. 5. J. Rahman-Yildir, B. Fischer, J. Breitkreutz (2022). Development and optimization of sustained-release drug-loaded intravesical inserts via semi-solid micro-extrusion 3D printing for bladder targeting, Int. J. Pharm. 622: 121849 (2022)
Volunteer work in scientific organisations and academic self-government (past 5 years)	President and Board Member of International Association of Pharmaceutical Technology and Industrial Pharmacy (APV e.V.), Mainz, Germany, since 2010 Scientific board member of Drug Development and Innovation Center (DDIC), Leverkusen, Germany, since 2017 Chair of PaedF group at European Directorate for Quality of Medicines (EDQM), Straßburg, France, since 2014 Member of Editorial Advisory Board of European Journal of Pharmaceutics and Biopharmaceutics, Drug Delvelopment and Industrial Pharmacy, AAPS PharmSciTech, Journal of Pharmaceutical and Biomedical Analysis Vice-chair of Pharmacy department at HHU, since 2014 Capacity commissioner of Pharmacy department at HHU, since 2005

Dr. Björn Fischer	
Position	Research and Teaching Manager
Academic CV	Present position, Research and Teaching Manager, Institute of Pharmaceutics and Biopharmaceutics, University of Düsseldorf, since 2017 Promotion: Dr. rer.nat., Physical Chemistry, University of Düsseldorf, 2015 Diplom-Chemiker, Institute of Physical Chemistry, University of Düsseldorf, 2008-2016 Studies of Chemistry and Business Chemistry, University of Düsseldorf, 2000-2007
Additional professions	CEO of FISCHER GmbH – Raman Spectroscopic Services, Meerbusch, Germany, since 2017 Founder and shareholder of Lico Analytics GmbH, Düsseldorf, Germany, 2020-2022 Founder and shareholder of Fischer & Bettermann PartG, Düsseldorf, Germany, 2010-2020
Recent research topics	Development and validation of a total reflection resonance Raman fluorescence detector for liquid chromatography in pharmaceutical quality control (Industrial Collective Research, 21280 N, 2020-2022) Investigation of the influence of polymers on a terrestrial ecosystem using the example of mulch films used in agriculture (European Fund for Regional Development, EFRE-0801172, 2019-2022) New areas of application for the LAB measurement method in the fields of quality control and analytics (Innovative & Digital SME, 005-2012-0180_1289, 2021) Development of a highly selective and ultrasensitive method for the quantitative determination of selected hormones in water based on fluorescence detection (Industrial Collective Research, 19681 N, 2017-2020)
Selected publications	J. Thissen, D. Klassen, P. Constantinidis, M.C. Hacker, J. Breitkreutz, T. Teutenberg, B. Fischer (2023), Online Coupling of Size Exclusion Chromatography to Capillary Enhanced Raman Spectroscopy for the Analysis of Proteins and Biopharmaceutical Drug Products, Anal. Chem., 95, 17868-17877. L. Wurm, B. Fischer, V. Neuschmelting, D. Reinecke, I. Fischer, R.S. Croner, R. Goldbrunner, M.C. Hacker, J. Dybas, U.D. Kahlert (2023), Rapid, label-free classification of glioblastoma differentiation status combining confocal

	Raman spectroscopy and machine learning, Analyst, 148, 6109-6119. M. Wenzel, B. Fischer, G. Renner, J. Schoettl, C. Wolf, J. Schramm, T.C. Schmidt, J. Tuerk (2022), Efficient and sustainable microplastics analysis for environmental samples using flotation for sample pre-treatment, Green Analytical Chemistry, 3, 100044. D. Kottke, B.B. Burckhardt, T.C. Knaab, J. Breitkreutz, B. Fischer (2021). Development and evaluation of a composite dosage form containing desmopressin acetate for buccal administration, Int. J. Pharm.: X, 3, 100082. D. Kottke, B.B. Burckhardt, J. Breitkreutz, B. Fischer (2021). Application and validation of a coaxial liquid core waveguide fluorescence detector for the permeation analysis of desmopressin acetate, Talanta, 226, 122145.
Volunteer work in scientific organisations and academic self-government (past 5 years)	n.a.

Prof. Dr. Holger Gohlke	
Position	University Professor (W2)
Academic CV	Present position: W2 University of Düsseldorf, since 2009 and Head of NIC Research Group, Forschungszentrum Jülich, since 2017 Declined professorship/Chair, University of Southampton, UK, 2012 Professorship: W2, University Kiel 2008-2009 Declined Senior Lecturer, University College Dublin, Ireland, 2008 Professorship: W1, University Frankfurt, 2003-2008 Post-doc: The Scripps Research Institute, La Jolla, CA, USA, 2001-2003 and University Marburg, 2000-2001 Promotion: Dr. rer.nat., University Marburg, 2000 Diplomchemiker (Dipl.-Ing.), Technical University Darmstadt, 1997 Approbierter Apotheker (Pharmacy License), University of Münster,1992
Additional professions	n.a.
Recent research topics	1. Structure, dynamics, and energetics: molecular recognition of biomacromolecules as a prerequisite to understand molecular mechanisms (SFB 974, SFB 1208, SPP 1710, FOR 2518) 2. Analyzing binding interface regions, “high information-content screening”, and modulating protein-protein interactions as means of target-oriented drug design (GRK 2158) 3. Modeling flexibility and plasticity of biomolecules as a basis for rational protein engineering and identification of allosteric mechanisms (CLIB, BioSC, Pfizer)
Selected publications	Pagani, G., Pereira, J.P.V., Stoldt, V.R., Beck, A., Scharf, R.E., Gohlke, H. (2018) The human platelet antigen-1b variant of αIIbβ3 allosterically shifts the dynamic conformational equilibrium of this integrin toward the active state. J. Biol. Chem. DOI: 10.1074/jbc.RA118.002149. Pfleger, C., Minges, A., Boehm, M., McClendon, C.L., Torella, R., Gohlke, H. (2017) Ensemble- and rigidity theory-based perturbation approach to analyze dynamic allostery. J. Chem. Theory Comput. 13, 6343-6357. Frieg, B., Görg, B., Homeyer, N., Keitel, V., Häussinger, D., Gohlke, H. (2016) Molecular mechanisms of glutamine

	synthetase mutations that lead to clinically relevant pathologies. PLOS Comp. Biol. 12, e1004693. Gohlke, H., Schmitz, B., Sommerfeld, A., Reinehr, R., Häussinger, D. (2013) α5ß1-Integrins are sensors for tauroursodeoxycholic acid in hepatocytes. Hepatology 57, 1117–1129. Kalinin, S., Peulen, T., Sindbert, S., Rothwell, P.J., Berger, S., Restle, T., Goody, R.S., Gohlke, H., Seidel, C.A.M. (2012) A toolkit and benchmark study for FRET-restrained high-precision structural modeling. Nature Methods 9, 1218–1225.
Volunteer work in scientific organisations and academic self-government (past 5 years)	Managing Director, Institute for Pharm. and Med. Chemistry, Heinrich-Heine-Universität, 2015-2017 Member of the "Fakultätsrat der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität", 2015-2017 Member of the „Studienbeirat der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität", as of 2016 Leader of project area B, Collaborative research center „Kommunikation und Systemrelevanz bei Leberschädigung und Regeneration" (SFB 974), as of 2016 Co-Speaker "integriertes Graduiertenkolleg" (iGK), Collaborative research center „Kommunikation und Systemrelevanz bei Leberschädigung und Regeneration" (SFB 974), as of 2016 Member of the Steering Committee, Collaborative research center „Identität und Dynamik von Membransystemen – Von Molekülen zu zellulären Funktionen" (SFB 1208), as of 2016 Member of the committee „Jülicher Exzellenzpreis", as of 2017

Jun.-Prof. Dr. Michael Hacker	
Position	Junior-Professor (W1)
Academic CV	Present: Professorship (W1), HHU Düsseldorf, since 2019 Habilitation in Pharmaceutical Technology, University of Leipzig, 2016 Group leader at University of Leipzig, Pharmaceutical Technology, 2007-2019 Post-doc: Rice University, Houston (Tx), USA, 2004-2007 Promotion: Dr. rer.nat., Pharmaceutical Technology, University of Regensburg, 2004 Professional Pharmacy License, 1999 Studies of Pharmacy, University of Erlangen-Nuremberg (FAU), 1993-1998
Additional professions	n.a.
Recent research topics	Macromer-based biomaterials for regeneration and drug delivery (DFG TRR67/A1, AiF ZIM VDI: 16KN056824, SMWK, SAB) Oligomeric amphiphiles for colloid and antinbody stabilization (SAB, DDiC/Invite) Injectable hydrogels as regenerative matrices (DFG HA 4444/1-1)
Selected publications	1. Wenzel B, Schmid M, Teodoro R, Moldovan RP, Lai TH, Mitrach F, Kopka K, Fischer B, Schulz-Siegmund M, Brust P, Hacker MC. Radiofluorination of an Anionic, Azide-Functionalized Teroligomer by Copper-Catalyzed Azide-Alkyne Cycloaddition. Nanomaterials 13(14):2095 (2023) 2. Vejjasilpa K, Maqsood I, Schulz-Siegmund M, Hacker MC. Adjustable Thermo-Responsive, Cell-Adhesive Tissue Engineering Scaffolds for Cell Stimulation through Periodic Changes in Culture Temperature. Int. J. Mol. Sci. 24(1) (2022) 3. Krieghoff J, Kascholke C, Loth R, Starke A, Koenig A, Schulz-Siegmund M, Hacker MC. Composition-controlled degradation behavior of macroporous scaffolds from three-armed biodegradable macromers. Polym. Degrad. Stabil. 195:109775 (2022) 4. Nawaz HA, Schröck K, Schmid M, Krieghoff J, Maqsood I, Kascholke C, Kohn-Polster C, Schulz-Siegmund M, Hacker MC. Injectable oligomer-cross-linked gelatine hydrogels via anhydride-amine-conjugation. J Mater Chem B. 9(9):2295-2307 (2021) 5. Kascholke C, Hendrikx S, Flath T, Kuzmenka D, Dörfler HM, Schumann D, Gressenbuch M, Schulze FP, Schulz-

	Siegmund M, Hacker MC. Biodegradable and adjustable sol-gel glass-based hybrid scaffolds from multi-armed oligomeric building blocks. Acta Biomater. 63:336-349 (2017)
Volunteer work in scientific organisations and academic self-government (past 5 years)	Treasurer, Controlled Release Society German Chapter e.V., since 2009 10/2016 - 10/2019: Academic advisor for pharmacy at the University of Leipzig 10/2016 - 10/2017: Elected member of the Council of the Faculty of Biosciences, Pharmacy and Psychology at University of Leipzig

Prof. Dr. Rainer Kalscheuer	
Position	University Professor (W2)
Academic CV	Present position (W2), University of Düsseldorf, since 2015 Independent junior research group leader, University of Düsseldorf, 2010 Post-doc: Howard Hughes Medical Institute at the Albert Einstein College of Medicine, USA, 2005 Post-doc: University of Münster, 2003 Promotion: Dr. rer.nat., Biology, University of Münster, 2003 Diploma in Biology, University of Münster, 1998
Additional professions	n.a.
Recent research topics	Elucidation of the mode-of-action of antimicrobial natural compounds (DFG RTG 2158, 2016 – 2021) Identification of antitubercular natural substances (BMBF 16GW0109, 2015 – 2018) Analysis of novel potential antibiotic targets in *Mycobacterium tuberculosis* (Jürgen Manchot Foundation, 2013 – 2016) Function of ATP binding cassette (ABC) transporters in *Mycobacterium tuberculosis* (DFG KA 2259/2-1, 2011 – 2014)
Selected publications	1. Rehberg N, Akone HS, Ioerger TR, Erlenkamp G, Daletos G, Gohlke H, Proksch P, Kalscheuer R (2018) Chlorflavonin targets acetohydroxyacid synthase catalytic subunit IlvB1 for synergistic killing of *Mycobacterium tuberculosis*. ACS Infect Dis. 4:123-134 doi: 10.1021/acsinfecdis.7b00055. 2. Korte J, Alber M, Trujillo CM, Syson K, Koliwer-Brandl H, Deenen R, Köhrer K, DeJesus MA, Hartman T, Jacobs WR Jr, Bornemann S, Ioerger TR, Ehrt S, Kalscheuer R (2016) Trehalose-6-phosphate-mediated toxicity determines essentiality of OtsB2 in *Mycobacterium tuberculosis* in vitro and in mice. PLoS Pathog. 12:e1006043. 3. Koliwer-Brandl H, Syson K, van de Weerd R, Chandra G, Appelmelk B, Alber M, Ioerger TR, Jacobs Jr. WR, Geurtsen J, Bornemann S, Kalscheuer R (2016) Metabolic network for the biosynthesis of intra- and extracellular α-glucans required for virulence of *Mycobacterium tuberculosis*. PloS Pathog. 12: e1005768.

	4. Kalscheuer R*, Weinrick B, Veeraraghavan U, Besra GS, Jacobs Jr. WR* (2010) Trehalose-recycling ABC transporter LpqY-SugA-SugB-SugC is essential for virulence of *Mycobacterium tuberculosis*. Proc. Natl. Acad. Sci. USA 107: 21761–21766. *Co-Corresponding authors 5. Kalscheuer R, Syson K, Veeraraghavan U, Weinrick B, Biermann KE, Liu Z, Sacchettini JC, Bornemann S, Jacobs Jr. WR (2010) Self-poisoning of *Mycobacterium tuberculosis* by targeting GlgE in an alpha-glucan pathway. Nat. Chem. Biol. 6: 376-384.
Volunteer work in scientific organisations and academic self-government (past 5 years)	Stipendiate commissioner of Pharmacy department at HHU, since 2017

Prof. Dr. Matthias Kassack	
Position	University Professor (W2)
Academic CV	Present position (W2), University of Düsseldorf, since 2006 Declined professorship (W3), University of Hamburg, 2010 Habilitation in Pharmaceutical and Medicinal Chemistry, University of Bonn, 2003 Post-doc: University of California San Francisco, USA, 1994-1996 Promotion: Dr. rer.nat., Pharmaceutical Chemistry, University of Bonn,1993 Approbierter Apotheker (Pharmacy License), University of Regensburg,1989
Additional professions	n.a.
Recent research topics	Chemoresistance of solid cancers and combinatorial strategies to overcome resistance (member of GRK2158, 2016-2025). Development of class IIa selective histone deacetylase inhibitors with chemosensitizing properties as anticancer agents (2016-2019, DFG KA1942-1) Development of subtype class I-selective histone deacetylase inhibitors and degraders for the reversion and prevention of therapy resistance in cancer (2022-2025, DFG KA 1942-2)
Selected publications	1. Asfaha Y, Bollmann LM, Skerhut AJ, Fischer F, Horstick N, Roth D, Wecker M, Mammen C, Smits SHJ, Fluegen G, Kassack MU#, Kurz T#. (#Shared senior authorship). 5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib. Eur J Med Chem. 2024; 263:115907. 2. Schrenk C, Bollmann LM, Haist C, Bister A, Wiek C, Wecker M, Roth D, Petzsch P, Köhrer K, Hamacher A, Hanenberg H, Fluegen G, Kassack MU. Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells. Int J Mol Sci. 2023; 24(6): 5553. 3. Bollmann LM, Skerhut AJ, Asfaha Y, Horstick N, Hanenberg H, Hamacher A, Kurz T, Kassack MU. The novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 is synergistic with Bortezomib in Leukemia Cell Lines. Int J Mol Sciences. 2022; 23(21):13398.

	4. Gohr K, Hamacher A, Engelke LH, Kassack MU. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. BMC Cancer 2017; 17(1): 711. 5. Gosepath EM, Eckstein N, Hamacher A, Servan K, von Jonquieres G, Lage H, Györffy B, Royer HD, Kassack MU. Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1. Int J Cancer. 2008; 123(9): 2013-9.
Volunteer work in scientific organisations and academic self-government (past 5 years)	Head of Examination Comittee for the Second State Exam for Pharmaceutical Sciences.

Prof. Dr. Thomas Kurz	
Position	University Professor (W2)
Academic CV	Present position (W2, since 2007), University of Düsseldorf Habilitation in Pharmaceutical Chemistry, University of Hamburg, 2007 Post-doc: University of Hamburg, 2001-2002 Post-doc: University of Florida, USA, 2000-2001 Promotion: Dr. rer.nat., Pharmaceutical Chemistry, University of Hamburg,1999 Approbierter Apotheker (Pharmacy License), 1996 Pharmacy studies, University of Hamburg,1990-1995
Additional professions	
Recent research topics	Malaria and epigenetic drug discovery, design and synthesis of metalloenzyme inhibitors and peptidomimetics
Selected publications	1. Knaab TC, Held J, Burckhardt BB, Rubiano K, Okombo J, Yeo T, Mok S, Uhlemann A, Lungerich B, Fischli C, Carvalho LP, Mordmüller B, Wittlin S, Fidock DA., Kurz T (2021). 3-Hydroxy-propanamidines, a New Class of Orally Active Antimalarials Targeting Plasmodium falciparum. J. Med. Chem. 64, 6, 3035–3047. 2. Bhatia S, Spanier L, Bickel D, Dienstbier N, Woloschin V, Vogt M, Pols H, Lungerich B, Reiners J, Aghaallaei N, Diedrich D, Frieg B, Diecks JS, Bopp B, Lang F, Gopalswamy M, Loschwitz J, Bajohgli B, Skokowa J, Borkhardt A, Hauer J, Hansen FK, Smits SHJ, Jose J, Gohlke H, Kurz T (2022). Development of a First-in-Class Small-Molecule Inhibitor of the C-Terminal Hsp90 Dimerization. ACS Cent. Sci. 8, 636–655. 3. Marquardt V, Theruvath J, Pauck D, Picard D, Qin N, Blümel L, Maue M, Bartl J, Ahmadov U, Langini M, Meyer F-D, Cole A, Cruz-Cruz J, Graef CM, Wölfl M, Milde T, Witt O, Erdreich-Epstein A, Leprivier G, Kahlert U, Stefanski A, Stühler K, Keir ST, Bigner DD, Hauer J, Beez T, Knobbe-Thomsen CB, Fischer U, Felsberg J, Hansen FK, Vibhakar R, Venkatraman S, Cheshier SH, Reifenberger G, Borkhardt A, Kurz T, Remke M, Mitra S (2023). Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. J. Immunother. Cancer. 11:e005871.

	4. de Carvalho, LP; Niepoth E, Mavraj-Husejni A, Kreidenweiss A, Herrmann J, Müller R, Knaab T, Burckhardt BB, Kurz T, Held J. (2023). Quantification of Plasmodium falciparum HPR-2 as an alternative method to [3H] hypoxanthine incorporation to measure the parasite reduction ratio in vitro. Int J Antimicrob Agents. 62 (3), 106894. 5. Asfaha Y, Bollmann LM, Skerhut AJ, Fischer F, Horstick N, Roth D, Wecker M, Mammen C, Smits SHJ, Fluegen G, Kassack MU, Kurz T (2024). 5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib. Eur. J. Med. Chem. 263, 115907.
Volunteer work in scientific organisations and academic self-government (past 5 years)	Scientific Editor of “The Archive for Organic Chemistry” (Arkivoc) since 2009 Member of the Arkivoc Control Board since 2009

Prof. Dr. Anne Seidlitz	
Position	University Professor (W2)
Academic CV	Present position (W2), University of Düsseldorf, since 2021 Substitute Professor, University of Jena, 2020-2021 Habilitation in Pharmaceutical Technology, University of Greifswald, 2015 Promotion: Dr. rer.nat., Pharmaceutical Technology, University of Greifswald, 2009 Diploma in Pharmacy, University of Greifswald, 2003 Professional license as a pharmacist, 2003 Studies of Pharmacy, University of Greifswald, 1998-2003
Additional professions	Associate editor for the Journal of Drug Delivery Science and Technology, since 2022 Qualified person at Hospital Pharmacy University Medicine Greifswald, 2009-2011 Scientist galenics department at Arzneimittelwerke Altona AG, Hamburg, 2003-2005
Recent research topics	3D printing of pharmaceuticals (Dr. Hans-Messer-Stiftung 2024-2025) AGePOP - Drug Absorption in Geriatric Patients and Older People (European Commission Innovative Training Network 2021-2024) „RESPONSE Partnerschaft für Innovation in der Implantattechnologie (BMBF Zwanzig20 – Partnerschaft für Innovation, 2014-2022)
Selected publications	1. J. Krause, V. Domsta V, M. Ulbricht, P. Schick, A. Seidlitz (2024). A case study to investigate the influence of extrusion temperature, 3D printing parameters and the use of antioxidants on the degradation of dexamethasone. J. Drug Deliv. Sci. Technol. 92:105394. 2. V. Domsta, C Hänsch, S. Lenz, Z. Gao, F. Matin-Mann, V. Scheper, T. Lenarz, A. Seidlitz (2023). The Influence of Shape Parameters on Unidirectional Drug Release from 3D Printed Implants and Prediction of Release from Implants with Individualized Shapes. Pharmaceutics. 15: 1276. 3. T. Auel, L.P. Scherke, S. Hadlich, S. Mouchantat, M. Grimm, W. Weitschies, A. Seidlitz (2023). Ex Vivo Visualization of Distribution of Intravitreal Injections in the

	Porcine Vitreous and Hydrogels Simulating the Vitreous. Pharmaceutics. 15: 786. 4. V. Domsta, J. Krause, W. Weitschies, A. Seidlitz (2022). 3D Printing of Paracetamol Suppositories: An Automated Manufacturing Technique for Individualized Therapy. Pharmaceutics. 14: 2676. 5. F. Matin-Mann, Z. Gao, J. Schwieger, M. Ulbricht, V. Domsta, S. Senekowitsch, W. Weitschies, A. Seidlitz, K. Doll, M. Stiesch, T. Lenarz, V. Scheper (2022). Individualized, Additively Manufactured Drug-Releasing External Ear Canal Implant for Prevention of Postoperative Restenosis: Development, In Vitro Testing, and Proof of Concept in an Individual Curative Trial. Pharmaceutics. 14: 1242.
Volunteer work in scientific organisations and academic self-government (past 5 years)	Scientific advisory board of the Federal Chamber of Pharmacists, Berlin International Asssociation of Pharmaceutical Technologgy (APV) task force additive manufacturing, Mainz European Federation for Pharmaceutical Sciences (EUFEPS) Network on Bioabailability and Biopharmaceutics, Frankfurt Scientific board member of Drug Development and Innovation Center (DDIC), Leverkusen Supervisor for qualification as specialised pharmacist in pharmaceutical analytics and technology

Prof. Dr. Dr. h.c. Holger Stark	
Position	University Professor (W3)
Academic CV	Present position (W3), University of Düsseldorf, since 2013 Honorary Doctorate of the University of Nis, Serbia, 2016 Visiting Professor, Universita` di Catania/Sicily, Italy, 2011 Rejected Professorship at Leopold Franzens University Innsbruck/Austria, 2008 Full Professorship (W3) Goethe University Frankfurt, 2007 Rejected Professorship Technical University Carolo Wilhemina zu Braunschweig, 2005 Full Professorship (C3) Goethe University, 2000 Assistant Professor (C1) Free University Berlin, 1993-1999 Post-doc: Free University of Berlin, 1992-1993 PhD; Dr. rer nat, Free University of Berlin, 1991 Approbierter Apotheker (Pharmacy License), Free University of Berlin,1987
Additional professions	*MCULE* – Ultimate Database Project, Budapest/Hungary, Advisory Board Member, since 2017 Psites Pharma GmbH, 2011- 2015, Co-founder, Chairman scientific advisory board Warburg Glycomed GmbH, 2007 – 2014, Co-founder, Chairman scientific advisory board Archiv der Pharmazie – Chemistry in Life Sciences, Editor-in-Chief, since 2004 Pharmakon – Arzneimittel in Wissenschaft und Praxis, Guest Editor 2014, 2018
Recent research topics	Medicinal Chemistry: Drug research for CNS drugs/neurotransmitters, dopamine receptor subtypes, histamine receptor subtypes (having Pitolisant (Wakix®) into market (EMA)), NMDA receptors, lipids, sphingolipids, biomarkers (fluorescence ligands), radioligands (PET, SPECT), prodrugs, partial agonists, inverse agonists, allosteric modulators, hybrid compounds, metabolic enzymes, Parkinson's disease, Alzheimer's disease, drug addiction, inflammation, immunology etc
Selected publications	1. P. Panula, P. L. Chazot, M. Cowart, R. Gutzmer, R. Leurs, W. L.S. Liu, H. Stark, R. L. Thurmond, H. L. Haas. International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. *Pharmacol. Rev*. 2015, *67*, 601-655 2. S. Hagenow, A. Stasiak, R. R. Ramsay, H. Stark. Ciproxifan, a Histamine H_3 Receptor Antagonist,

	Reversibly Inhibits Monoamine Oxidase A and B. *Sci. Rep*. 2017, 40541. (open access) 3. S. Butini, K. Nikolic, S. Kassel, H. Brückmann, S. Filipic, D. Agbaba, S. Gemma, S. Brogi, M. Brindisi, G. Campiani, H. Stark. Polypharmacology of Dopamine Receptor Ligands. *Prog. Neurobiol*. 2016, *142*, 68-103 (open access) 4. Ó. M. Bautista-Aguilera, S. Hagenow, A. Palomino-Antolin, V. Farré-Alins, L. Ismaili, P.-L. Joffrin, M. L. Jimeno, O. Soukup, J. Janockova, L. Kalinowsky, E. Proschak, I. Iriepa, I. Moraleda, J. S. Schwed, A. R. Martinez, F. López-Muñoz, M. Chioua, J. Egea, R. R. Ramsay, J. Marco-Contelles, H. Stark. Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H_3R Antagonism for Neurodegenerative Diseases. *Angew. Chem. Int. Ed*. 2017, *56*, 12765-12769. 5. D. Vogt, H. Stark. Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism. *Med. Res. Rev*. 2017, *37*, 3-51.
Volunteer work in scientific organisations and academic self-government (past 5 years)	Board Member EU COST Action BM0806 – Recent advances in histamine H4R research, work group leader (2009-2013) Board Member EU COST Action CM1103 – Structure based drug design for diagnosis and treatment of neurological diseases (2011-2015) Board Member EU COST Action CM1207 – GLISTEN: GPCR-Ligand interaction, structures and transmembrane signaling (2013-2017) Board Member EU COST Action CA15135 – Multi-target paradigm for innovative ligand identification in the drug discovery process, since 2016 Chairman of Pharmacy departments at HHU, since 2015 PhD commission of faculty, since 2016 Special acess to higher education in pharmacy, HHU, since 2014 Public affairs in pharmacy, HHU, since 2015 German Pharmaceutical Society, Chairman regional group Rheinland, since 2015 Organizer of student excursion *PharmaNauten*, since 2015

Prof. Dr. Nicole Teusch	
Position	University Professor (W2 tt W3)
Academic CV	Since 04/2022 University Professor for Pharmaceutical Biology and Biotechnology (W2 tt W3), HHU, Germany 04/2019 - 03/2022 Professor (W2) for Biomedical Research, Osnabrück University, Germany 02/2011 – 03/2019 Professor (W2) for Biopharmaceutical Chemistry, TH Köln, Germany 04/1999 – 07/2002 PhD at The Scripps Research Institute (TSRI), La Jolla, CA, USA 12/1998 Diploma in Biology, Johannes-Gutenberg University Mainz, Germany
Additional professions	01/2008 – 01/2011 Group Leader, Bayer AG/ Pharma division, Preclinical Drug Discovery, Wuppertal, Germany 01/2003 – 12/2007 Lab Head and Preclinical Project Lead, Abbott Laboratories, Preclinical Drug Discovery, Chicago, USA and Ludwigshafen, Germany
Recent research topics	Development of novel human three-dimensional engineered tissues considering cellular heterogeneity amenable for miniaturized and semiautomated drug characterization Vascularization of 3D tumor organoids via chip technology for dynamic drug administration or immune cell infiltration and differentiation studies within the tumor microenvironment 3D human full-thickness skin model: Further development towards novel disease models for skin inflammation and (diabetic) neuropathy including iPSC-derived cell types Isolation, purification of natural products e.g. from endophytic fungi from either the marine habitat or form plants and bioactivity-guided screening for therapeutic indications related to the models described above
Selected publications	1. El-Kashef D, Obidake DD, Schiedlauske K, Deipenbrock A, Scharf S, Wang H, Naumann D, Friedrich D, Miljanovic S, Sohi T, Janiak C, Pfeffer K & Teusch N, Indole diketopiperazine alkaloids from the marine sediment-derived fungus *Aspergillus chevalieri* against pancreatic ductal adenocarcinoma. Marine Drugs 2023, 22(1)

	2. Hoelken JM, Friedrick K, Merkel M, Blasius N, Engels U, Buhl T, Mewes KR, Vierkotten L & Teusch N, A human 3D immune competent full-thickness skin model mimicking dermal dendritic cell activation. Frontiers in Immunology 2023, 14, 1276151 3. Hoelken JM & Teusch N, The monocytic cell line THP-1 as a validated and robust surrogate model for human dendritic cells. International Journal of Molecular Sciences, 2023, 24 (2), 1452 4. Reimche I, Yu H, Ariantari NP, Liu Z, Merkens K, Rotfuß S, Peter K, Jungwirth U, Bauer N, Kiefer F, Neudörfl JM, Schmalz HG, Proksch P, Teusch N, Phenanthroindolizidine alkaloids isolated from Tylophora ovata as potent inhibitors of inflammation, spheroid growth, and invasion of triple-negative breast cancer. International Journal of Molecular Sciences, 2022, 23(18), 10319 5. Xie B, Hänsel J, Mundorf V, Betz J, Reimche I, Erkan M, Büdeyri I, Barlas T, Gesell A, De Bank P, Teusch N, Mrsny R*, Pseudopterosin and tylophorinine suppress cell growth in 3D spheroid co-culture models of pancreatic ductal adenocarcinoma. Bioengineering 2020, 7 (2), 57.
Volunteer work in scientific organisations and academic self-government (past 5 years)	Managing director of the Institute of Pharmaceutical Biology and Biotechnology, HHU, since 04/2022 Member of the “Fakultätsrat der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität“, since 09/2023 Member of the Scientific Advisory Board of the Division "Natural Substances with Biological Activity" of the German Society for Chemical Engineering and Biotechnology (DECHEMA), since 09/2019

2. Lecturers from Drug Delivery Innovation Center (DDIC) and Invite GmbH

Name	Profession	Present Position
Sara Badawi	Pharmacist	Research Fellow, Invite
Carl-Helmut Coulon	Computer Scientist	Head of Future Manufacturing Concepts, Invite
Malin Hermeling	Chemist	Research Fellow, Invite
Dr. Tim Lillotte	Pharmacist	Technical Manager at DDIC, Invite GmbH
A. Christofer Mentrup	Pharmacist	Research Fellow, DDIC
Dr. Uwe Muenster	Pharmacist	Scientific Coordinator, Invite GmbH
Stephanie Scheele	Chemist	Research Fellow, Invite
Dr. Ildiko Terebesi	Pharmacist	CEO of Invite GmbH
Isidora Vuckovic	Chemist	Research Fellow, Invite

3. Lecturers from Pharmaceutical Companies

Name	Profession	Present Position
Dr. Kathrin Bartscher	Pharmacist	Chief Scientific Officer, Board Member, NextPharma, Düsseldorf, Germany
Dr. Alexandra Baumann	Pharmacist	Head of Product Development and Regulatory Affairs, NextPharma, Waltrop, Germany
Dr. Martin Bultmann	Pharmacist	Director Process Engineering Sciences New Biological Entities, AbbVie, Ludwigshafen
Dr. Felix Ditzinger	Pharmacist	Drug Product Lead, Formulation & Process Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland
Dr. Stefanie Dohrn	Engineer	AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Dr. Dejan Djuric	Engineer	Pharmaceutical Process Technology Manager SOL1, Bayer AG, Leverkusen, Germany
Dr. Carsten Griebel	Chemist	Head Chemical Development, Grünenthal GmbH, Aachen, Germany
Dr. Christian Große	Chemist	Head of Solid State Laboratory, Grünenthal GmbH, Aachen, Germany
Dr. Isabell Immohr	Pharmacist	Director Pharmaceutical Development, NextPharma, Düsseldorf, Germany
Claudia Graneis	Pharmacist	Lab Head FG Testing & Retention Samples, Bayer AG, Leverkusen, Germany
Dr. Michael Herbig	Pharmacist, MBA	Co-founder and CEO, RaDeS GmbH, Hamburg, Germany
Dr. Alexandra Hertrampf	Pharmacist	Director Liquid Production, Merck Healthcare KgaA, Darmstadt, Germany
Dr. Kai Hückstädt	Pharmacist	Head of Manufacturing, Bayer AG, Leverkusen, Germany
Dr. Markus Krumme	Pharmacist	Head of Continuous Manufacturing, Novartis, Basel, Switzerland

Dr. Hans-Georg Lerchen	Chemist	Principal Scientist Medicinal Chemistry, Bayer HealthCare, Wuppertal, Germany
Dr. Yuta Mayazaki	Pharmacist	Head of Formulation Development, Ono Pharmaceuticals, Osaka, Japan
Dr. John Maggioni	Chemical Engineer	Expert Crystallization, Bayer AG, Leverkusen, Germany
Kosima Niepenberg	Pharmacist	Head of Manufacturing, Lindo-pharm GmbH, Hilden, Germany
Dr. Christoph Nüboldt	Engineer	Expert Formulation Technology, Bayer AG, Leverkusen, Germany
Dr. Susanne Page	Pharmacist	Head of Formulation and Process Research and Development. Roche, Basel, Switzerland
Dr. Victoria Pauli	Pharmacist	Senior Expert Science and Technology, Continous Manufacturing, Novartis, Basel, Switzerland
Dr. Virpi Puonti	Pharmacist	Head of Pharmaceutical Development, NextPharma Tampere, Finland
Dr. Bernd Riedl	Chemist	Vice President Medicinal Chemistry, Bayer HealthCare, Wuppertal, Germany
Fritz Röder	Engineer	Site Account Engineer, Merck Healthcare KgaA, Darmstadt, Germany
Dr. Berthold Rössler	Pharmacist	Qualified Person at Grünenthal Group, Grünenthal, Aachen, Germany
Rakulan Sivanesapillai	Engineer	Expert Modeling Formulation Processes, Bayer AG, Leverkusen, Germany
Ulrich Schmöe	Engineer	Global Engineering Director, NextPharma BidCo GmbH, Göttingen, Germany
Dr. Rok Sibanc	Pharmacist	Lab Head Formulation Development, Bayer AG, Wuppertal, Germany
Tobias Struller	Biochemist	Head of Validation, Simtra BioPharmaSolutions (Baxter), Halle, Germany

Dr. Leonie Wagner	Pharmacist	Formulation R&D Oral Dosage Forms, PTDC-F, F. Hoffmann-La Roche AG, Basel, Switzerland
Dr. Frank Wetterich	Chemist	Head Process Reseach & Development, Bayer AG, Wuppertal, Germany
Dr. Stefan Willmann	Pharmacist	Pharmacometrics/Modeling & Simulation, Bayer AG, Wuppertal, Germany
Dr. Emrah Yildir	Pharmacist	Business Development Manager, Labtec GmbH (Adhex), Langenfeld, Germany

4. Lecturers from Other Companies or Institutions

Name	Profession	Present Position
Andreas Altmeyer	Engineer	Head of Service Center, L.B. Bohle Maschinen und Verfahren GmbH, Ennigerloh, Germany
Dr. Dirk Bröcher	Chemical Engineer	European Patent and Trademark Attorney, Gille Hrabal, Düsseldorf, Germany
Dr. Tanja Butt	Biologist	Lead Product Management, Retsch GmbH, Hilden, Germany
Christian Gavranovic	Engineer	Lead Quality and Compliance, Pharma Process Technology (PPT), Mannheim, Germany
Dr. Hans-Jürgen Hamann	Pharmacist	Consultant, formerly Head of Product Development, Bayer Animal Health, Monheim, Germany
Veit Haustein	Engineer	Senior Project Manager, Otto Life Science Engineering GmbH, Nuremberg, Germany
Felix Hofmann	Chemist	Director Formulation & Application Services EMEA, Evonik Operations, Darmstadt, Germany
Ass.-Prof. Dr. Motoki Inoue	Pharmacist	Meiji Pharmaceutical University, Tokyo, Japan
Dr. Viviane Klingmann	Physician	Senior Paediatrician at University Childrens' Hospital, Duesseldorf, Germany
Dr. Thomas Lauterbach	Chemist and Pharmacist	Consultant, formerly Head of Clinical Operation Europe, UCB Pharma, Monheim, Germany
Bernhard Meir	Engineer	Head of Continuous Manufacturing, Gericke, Regensdorf, Switzerland
Dr. Christian Mühlenfeld	Pharmacist	Head of Life Sciences R&D Europe, Middle East & Africa, Ashland, Düsseldorf, Germany
Dr. Johanna Peters	Pharmacist	Project Manager Innovation Domain Cell & Tissue Systems, Creavis (Evonik AG), Singapore
Ass.-Prof. Julian Quodbach	Pharmacist	Assistant Professor, Department of Pharmaceutics, Utrecht University, The Netherlands

Daniel Sieber	Pharmacist	Technical Manager EMEA, DFE Pharma, Goch, Germany
Volker Roeder	Engineer	Principal Consultant, Arcondis, Reinach/Basel, Switzerland
Daniel Wothe	Engineer	Polarixpartner GmbH, Saarburg, Germany